Cullinan Therapeutics, Inc. (CGEM) research

Cullinan Therapeutics, Inc.
ShareXLinkedInReddit
Sector
Biotechnology
Last price
$21.35
As of

Cullinan Therapeutics, Inc. (CGEM): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-14.

As of . Source: SEC EDGAR filings for CGEM. Method and limitations.

SHARE THIS CARD

Share the CGEM intelligence card

A branded snapshot of CGEM: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion CGEM intelligence card preview
Post to X
LIVE TERMINAL

See CGEM live in the terminal

Track CGEM's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live CGEM terminal, free

Active signals for CGEM

FREE, NO ACCOUNT

Every signal on CGEM, as it fires

You are seeing 5 of 20 signals recorded on CGEM since 2026-05-16.

The five above all landed on 2026-09-06. The other 15 were recorded on 3 other days. 16 of the 20 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in CGEM (2026Q2)

Manager / securityMarket value% portfolioQoQ
CITADEL ADVISORS LLCCUSIP 230031106 · 2026Q2$7.2M0.00%,
MILLENNIUM MANAGEMENT LLCCUSIP 230031106 · 2026Q2$6.3M0.00%,
RENAISSANCE TECHNOLOGIES LLCCUSIP 230031106 · 2026Q2$6M0.01%,
TWO SIGMA INVESTMENTS, LPCUSIP 230031106 · 2026Q2$5M0.00%,
Point72 Asset Management, L.P.CUSIP 230031106 · 2026Q2$1.4M0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, CGEM

CGEM against its peers

CGEM's return on equity of -53.8% ranks in the 38th percentile of 11 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.

MetricCGEMPeer medianPercentilen
Revenue FYn/a146Mn/a6
Operating marginn/a-82.4%n/a6
Net marginn/a-81.9%n/a6
Return on equity-53.8%-38.3%3811

Peers (15): VOR, DRTS, RARE, IMTX, MAZE, ORIC, MGTX, REPL, MNKD, GLUE, ABSI, AVBP, LBRX, BCAX, JBIO. Left out: AKTS (no annual filing), SPTX (no annual filing), TRAX (no annual filing), AVLN (no annual filing), ODTX (no annual filing), LTGO (no annual filing), KALV (no annual filing), SLBT (no annual filing), APMD (no annual filing), OBX (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (CGEM: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more CGEM signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to CGEMand get the insider, 13F, options, and confluence read in one view.

Open the live CGEM terminal, free